BioCentury
ARTICLE | Clinical News

MGB Biopharma preclinical data

October 10, 2011 7:00 AM UTC

In a hamster model of CDAD, twice-daily 10 mg MGB-BP-3 given as a freebase suspension or as colonic delivery microparticles for 5 days led to mean survival times of 11.2 and >13 days, respectively, vs...